Product Description
intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization for End Stage Renal Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02032095)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Japan Blood Products Organization
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Guillain-Barre Syndrome|Kidney Failure, Chronic|Polymyositis|Dermatomyositis|Abortion, Spontaneous|Myasthenia Gravis|Muscle Weakness|Abortion, Habitual
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B211-11 | P3 |
Completed |
Abortion, Spontaneous|Abortion, Habitual |
2020-05-01 |
50% |
| B211-10 | P3 |
Completed |
Kidney Failure, Chronic |
2015-09-01 |
|
| B211-13 | P3 |
Completed |
Guillain-Barre Syndrome |
2015-09-01 |
|
| 0998-B1 | P3 |
Completed |
Muscle Weakness|Myasthenia Gravis |
2010-05-01 |